Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL8911285 | 0.94 | PGR (0.40) | KMT2APGRMEN1NPC1CHRNB2 | |
| Bicarbonate SCHEMBL8911279 | 0.94 | PGR (0.40) | KMT2APGRMEN1NPC1CHRNB2 | |
| Bicarbonate SCHEMBL8911277 | 0.94 | PGR (0.40) | KMT2APGRMEN1NPC1CHRNB2 | |
| SCHEMBL8911281 | 0.83 | PGR (0.40) | KMT2APGRMEN1NPC1CHRNB2 | |
| SCHEMBL8604785 | 0.83 | CYP11B1 (0.42) | KMT2AMEN1NPC1MAOBHTT | |
| SCHEMBL7282122 | 0.82 | PGR (0.39) | KMT2APGRMEN1NPC1CHRNB2 | |
| SCHEMBL10773101 | 0.81 | CA12 (0.40) | HTTMLYCDKEAP1NFE2L2 | |
| SCHEMBL2707534 | 0.80 | ALDH1A1 (0.48) | KMT2AMEN1MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL204330 | 0.80 | MLYCD (0.40) | HTTMLYCDALDH1A1 | |
| SCHEMBL7835897 | 0.80 | BCL2A1 (0.45) | MMP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-5852192-A | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1998-12-22 | — | — | US | disclosed |
| US-5650424-A | ANTIAGGLOMERANTS USING IMIDAZOLIDINDIONES | DR. KARL THOMAE GMBH (DE) | 1997-07-22 | — | — | US | disclosed |
| EP-0503548-B1 | Cyclic urea derivatives, medicaments contaning them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-06-04 | — | — | EP | disclosed |
| US-5478942-A | Antiinflammatory agents, antiagglomerants | KARL THOMAE GMBH (DE) | 1995-12-26 | — | — | US | disclosed |
| US-5276049-A | Treatment of thrombosis | DR. KARL THOMAE GMBH (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0503548-A1 | Cyclic urea derivatives, medicaments contaning them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | KMT2A 1232/4885PGR 3529/4885MEN1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.